Tackling the Last Mile: A major component to successfully establish radioligand therapy

Kelsey L. Pomykala, Marcus Würker and Ken Herrmann
Journal of Nuclear medicine December 2022, jnumed.122.264900; DOI: https://doi.org/10.2967/jnumed.122.264900

With two promising radioligand therapies recently approved by the Food & Drugs Administration (FDA) – Lutathera (177Lu-Dotatate) and Pluvicto (177Lu-PSMA-617) – the stage is set for a radioligand therapy renaissance.

The first difficult 25 miles of the marathon have been run […]. The last mile is to successfully delivery the therapy to patient.

>> Read the article